BioCentury
ARTICLE | Clinical News

Genmab starts HuMax-IL15 trials

October 3, 2001 7:00 AM UTC

Genmab (CSE:GEN, NMarkt:GE9D) said it has started in Denmark a Phase I/II trial of its HuMax-IL15 human antibody against IL-15 to treat rheumatoid arthritis. The 30-patient dose ranging trial will mea...